hsa-MicroRNA-28-5p Inhibits Diffuse Large B-Cell Lymphoma Cell Proliferation by Downregulating 14-3-3ζ Expression

Table 1

Features of 15 patients diagnosed with DLBCL with fresh and frozen samples.

Item	GCB group	ABC group	value
N	5	10	–
Age (years)
<50	2 (2/5, 40)	5 (5/10, 50)	1.000
>50	3 (3/5, 60)	5 (5/10, 50)
Gender, n (%)
Male	3 (3/5, 60)	8 (8/10, 80)	0.560
Female	2 (2/5, 40)	2 (2/10, 20)
Primary localization, n (%)
Intranodal	4 (5/5, 80)	6 (6/10, 60)	0.600
Extranodal	1 (1/5, 20)	4 (4/10, 40)
Laboratory parameter, mean ± SD (10^9/l)
Leukocytes	10.45 ± 4.01	5.91 ± 3.33	0.036∗
Hemoglobin	121.80 ± 22.20	103.90 ± 26.47	0.218
Thrombocyte	264.80 ± 110.25	119.60 ± 89.30	0.016∗
LDH increased, n (%)	2 (2/5, 40)	4 (4/10, 40)	1.000
B-symptoms, n (%)	1 (1/5, 20)	4 (4/10, 40)	0.007∗
Ann Arbor stage, n (%)
I∼II (early stage)	3 (3/5, 60)	2 (2/10,20)	0.251
III∼IV (late stage)	2 (2/5, 40)	8 (8/10, 80)
Bone marrow involvement, n (%)	0 (0)	2 (2/10, 20)	0.007∗
hsa-miRNA-28-5p, mean ± SD	0.502 ± 0.274	0.699 ± 0.382	0.566
YWHAZ, mean ± SD	1.252 ± 0.407	2.331 ± 0.811	0.004∗
Overall survival, n (%)	3 (3/5, 60)	8 (8/10, 80)	0.353